2. Immunology/Inflammation
  3. Interleukin Related
  4. Tagraxofusp

Tagraxofusp  (Synonyms: SL-401)

Cat. No.: HY-P99536

Molarity Calculator

Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM).

For research use only. We do not sell to patients.

Tagraxofusp Chemical Structure

Tagraxofusp Chemical Structure

CAS No. : 2055491-00-2

Size Stock
1 mg Get quote
5 mg Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Tagraxofusp Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM)[1].

IC50 & Target[1]

IL-3

 

In Vitro

Tagraxofusp (0-1367 pM; 72 h) inhibits pDCs viability, as well as pDC-induced proliferation of MM cells. Tagraxofusp (0-136.7 pM; 2-3 weeks) inhibits osteoclast formation and bone resorption, as well as stabilizes osteoblast formation[1].
Tagraxofusp (0-13.67 nM; 48 h) targets tumor-initiating stem-like cells in MM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tagraxofusp Related Antibodies

Cell Viability Assay[1]

Cell Line: Cancer stem-like cells in MM
Concentration: 0 nM, 0.013 nM, 0.13 nM, 1.3 nM, 13.67 nM
Incubation Time: 48 hours
Result: Inhibits cancer stem-like cells with s of 30 pM (pDCs), 50 nM (MM-SP-Oct4 cells), 75 pM (RPMI-8226-Oct4 cells), 350 pM (MM-SP cells), and 1367 pM (RPMI-8226 cells), respectively.
In Vivo

Tagraxofusp (12-50 μg/kg; i.v.; 5 times per week for 3 weeks) blocks pDC-induced tumor growth and prolongs SCID-hu mice survival in subcutaneous INA-6 MM xenograft model[1].
Tagraxofusp (16 μg/kg; i.v.; 5 times per week for 1 weeks) enhances the anti-MM activity of 2.5 mg/kg Pomalidomide in CB-17 mice of subcutaneous MM xenograft model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID-hu mice with INA-6 MM cells[1]
Dosage: 12 μg/kg, 16 μg/kg, 25 μg/kg and 50 μg/kg
Administration: Intravenous injection; for 5 consecutive days each week for 3 weeks
Result: Blocked pDC-induced tumor growth and prolonged mice survival at 12 μg/kg.
Showed well tolerance at 16 μg/kg, while higher doses resulted in body weight decrease and toxicity.
Animal Model: CB-17 mice with subcutaneous MM xenograft model[1]
Dosage: 16 μg/kg; with or without 2.5 mg/kg Pomalidomide (p.o.; 4 consecutive days weekly for 2 weeks)
Administration: Intravenous injection; dose at 5 consecutive days for first week
Result: Enhanced the anti-MM activity of proteasome inhibitor and immunomodulatory drug pomalidomide.
Clinical Trial
CAS No.
SMILES

[Tagraxofusp]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tagraxofusp Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tagraxofusp2055491-00-2SL-401SL401SL 401Interleukin RelatedILInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tagraxofusp
Cat. No.:
HY-P99536
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.